Time filter

Source Type

Dublin, Ireland

November 03, 2014 by admin in News Dr Richard Davis appointed in the newly created role of Chief Executive Officer Industry recognised clinical expert, Dr Marie Lindner appointed as a non-executive to the Board of Directors Trino Therapeutics lead candidate, PH46A, advances in an extended Phase I clinical trial DUBLIN, Ireland. 3rd November 2014 ...

Trino Therapeutics | Entity website

Trino Therapeutics is a spin-off company from the School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin(TCD). Launched in September 2011, itis supported by a syndicate of Venture Capital investors and local State Support thatincludes Fountain Healthcare Partners, The Wellcome Trust, Growcorp and Enterprise Ireland

Trino Therapeutics | Entity website

June 04, 2012by adminin NewsComments Off Dr Frankish and Dr Sheridan can announce that their paper on Trinos lead candidate, PH46A, has been published online, prior to print, in the Journal of Medicinal Chemistry, published by the American Chemical Society. The paper describes the chemistry and pharmacology of PH46A in two different models of IBD ...

Trino Therapeutics | Entity website

May 28, 2013 by admin in News TRINO THERAPEUTICS secures Series A investment of over9M ($12M) for a novel oral drug therapy for mild to moderate ulcerative colitis Irelands Trino Therapeutics secures major additional investment from new investors Fountain Healthcare Partners and founding investor the Wellcome Trust; Wellcome Trust will invest through the prestigious internationally competitive Strategic Read More

Discover hidden collaborations